Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms, Castration-Resistant × cabazitaxel × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7 Urinary Bladder Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer, Hereditary, 7 1 Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Prednisone 5 enzalutamide 4 Docetaxel 4 Abiraterone Acetate 3 olaparib 1 niraparib 1 fludrocortisone acetate 1 darolutamide 1 cabazitaxel 1 abiraterone 1 Rosuvastatin Calcium 1 Pluvicto 1 Pioglitazone 1 Omeprazole 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06353386 2026-03-13

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡